


## HPGDS inhibitor 2

Cat. No.:	HY-126134
CAS No.:	2101626-26-8
Molecular Formula:	C <sub>20</sub> H <sub>24</sub> F <sub>2</sub> N <sub>2</sub> O <sub>3</sub>
Molecular Weight:	378.41
Target:	PGE synthase
Pathway:	Immunology/Inflammation
Storage:	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 150 mg/mL (396.40 mM)  
\* "≥" means soluble, but saturation unknown.

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.6426 mL	13.2132 mL	26.4264 mL
	5 mM	0.5285 mL	2.6426 mL	5.2853 mL
	10 mM	0.2643 mL	1.3213 mL	2.6426 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (6.61 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.5 mg/mL (6.61 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (6.61 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

HPGDS inhibitor 2 is a highly potent and selective hematopoietic prostaglandin D synthase (H-PGDS) inhibitor with an IC<sub>50</sub> of 9.9 nM<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

IC<sub>50</sub>: 9.9 nM (H-PGDS)<sup>[1]</sup>

### REFERENCES

---

[1]. Deaton DN, et al. The discovery of quinoline-3-carboxamides as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors. *Bioorg Med Chem*. 2019 Apr 15;27(8):1456-1478.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA